* history of sars-cov-2 infection confirmed by pcr or serology is available at inclusion * a history of clinical episode suspecting a pcr-confirmed or unconfirmed covid-19 infection. * pregnancy and breastfeeding * allergy or contraindications to one of the 2 drugs in the study * known retinopathy * long congenital qt syndrome (or known in the family) * qtc or 450 ms in men, or 460 ms in women, if fc 55/mn (except in case of intense sport practice), if esv on baseline ecg, if qrs - or 120 ms, if ac/fa, if the pr or bav lengthening * history of severe ischemic heart disease or unbalanced heart failure. * clinically significant bradycardia known * known kidney or liver failure * known g6pd deficit * subject who received antiviral treatment in the 14 days prior to inclusion * subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion * hypokaliemia (\<= 3.5 mmol/l), increase in creatinine (\>=120 micromol/ll, increase in transaminases at baseline (\>=2n)

* history of sars-cov-2 infection confirmed by pcr or serology is available at inclusion * a history of clinical episode suspecting a pcr-confirmed or unconfirmed covid-19 infection. * pregnancy and breastfeeding * allergy or contraindications to one of the 2 drugs in the study * known retinopathy * long congenital qt syndrome (or known in the family) * qtc or 450 ms in men, or 460 ms in women, if fc 55/mn (except in case of intense sport practice), if esv on baseline ecg, if qrs - or 120 ms, if ac/fa, if the pr or bav lengthening * history of severe ischemic heart disease or unbalanced heart failure. * clinically significant bradycardia known * known kidney or liver failure * known g6pd deficit * subject who received antiviral treatment in the 14 days prior to inclusion * subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion * hypokaliemia (\<= 3.5 mmol/l), increase in creatinine (\>=120 micromol/ll, increase in transaminases at baseline (\>=2n)

- history of sars-cov-2 infection confirmed by pcr or serology is available at inclusion - a history of clinical episode suspecting a pcr-confirmed or unconfirmed covid-19 infection. - pregnancy and breastfeeding - allergy or contraindications to one of the 2 drugs in the study - known retinopathy - long congenital qt syndrome (or known in the family) - qtc or 450 ms in men, or 460 ms in women, if fc 55/mn (except in case of intense sport practice), if esv on baseline ecg, if qrs - or 120 ms, if ac/fa, if the pr or bav lengthening - history of severe ischemic heart disease or unbalanced heart failure. - clinically significant bradycardia known - known kidney or liver failure - known g6pd deficit - subject who received antiviral treatment in the 14 days prior to inclusion - subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion - hypokaliemia (<= 3.5 mmol/l), increase in creatinine (>=120 micromol/ll, increase in transaminases at baseline (>=2n)

- history of sars-cov-2 infection confirmed by pcr or serology is available at inclusion - a history of clinical episode suspecting a pcr-confirmed or unconfirmed covid-19 infection. - pregnancy and breastfeeding - allergy or contraindications to one of the 2 drugs in the study - known retinopathy - long congenital qt syndrome (or known in the family) - qtc or 450 ms in men, or 460 ms in women, if fc 55/mn (except in case of intense sport practice), if esv on baseline ecg, if qrs - or 120 ms, if ac/fa, if the pr or bav lengthening - history of severe ischemic heart disease or unbalanced heart failure. - clinically significant bradycardia known - known kidney or liver failure - known g6pd deficit - subject who received antiviral treatment in the 14 days prior to inclusion - subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion - hypokaliemia (<= 3.5 mmol/l), increase in creatinine (>=120 micromol/ll, increase in transaminases at baseline (>=2n)